Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Lactonization Is the Critical First Step in the Disposition of the 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitor Atorvastatin

Wolfgang Jacobsen, Bernd Kuhn, Andrea Soldner, Gabriele Kirchner, Karl-Fr. Sewing, Peter A. Kollman, Leslie Z. Benet and Uwe Christians
Drug Metabolism and Disposition November 2000, 28 (11) 1369-1378;
Wolfgang Jacobsen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernd Kuhn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Soldner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriele Kirchner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl-Fr. Sewing
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter A. Kollman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslie Z. Benet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Christians
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In an in vitro study, we compared the cytochrome P450 (CYP)-dependent metabolism and drug interactions of the acid and lactone forms of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor atorvastatin. Metabolism of atorvastatin acid and lactone by human liver microsomes resulted in para-hydroxy andortho-hydroxy metabolites. Both substrates were metabolized mainly by CYP3A4 and CYP3A5. Atorvastatin lactone had a significantly higher affinity to CYP3A4 than the acid (Km: para-hydroxy atorvastatin, 25.6 ± 5.0 μM; para-hydroxy atorvastatin lactone, 1.4 ± 0.2 μM;ortho-hydroxy atorvastatin, 29.7 ± 9.4 μM; andortho-hydroxy atorvastatin lactone, 3.9 ± 0.2 μM). Compared with atorvastatin acid, CYP-dependent metabolism of atorvastatin lactone to its para-hydroxy metabolite was 83-fold higher [formation CLint(Vmax/Km): lactone 2949 ± 3511 versus acid 35.5 ± 48.1 μl · min−1 · mg−1] and to itsortho-hydroxy metabolite was 20-fold higher (CLint: lactone 923 ± 965 versus acid 45.8 ± 59.1 μl · min−1 · mg−1). Atorvastatin lactone inhibited the metabolism of atorvastatin acid by human liver microsomes with an inhibition constant (Ki) of 0.9 μM while theKi for inhibition of atorvastatin by atorvastatin lactone was 90 μM. Binding free energy calculations of atorvastatin acid and atorvastatin lactone complexed with CYP3A4 revealed that the smaller desolvation energy of the neutral lactone compared with the anionic acid is the dominant contribution to the higher binding affinity of the lactone rather than an entropy advantage. Because atorvastatin lactone has a significantly higher metabolic clearance and the lactone is a strong inhibitor of atorvastatin acid metabolism, it can be expected that metabolism of the lactone is the relevant pathway for atorvastatin elimination and drug interactions. We hypothesize that most of the open acid metabolites present in human plasma are generated by interconversion of lactone metabolites.

Footnotes

  • Send reprint requests to: Uwe Christians, Department of Biopharmaceutical Sciences, University of California, San Francisco, CA 94143-0446. E-mail: uwec{at}itsa.ucsf.edu

  • W.J. and L.Z.B. were supported in part by National Institutes of Health Grant CA72006; B.K. was supported by a research scholarship of the German Academic Exchange Service (DAAD); G.I.K. and K.F.S. by the Deutsche Forschungsgemeinschaft, Grant SFB265 A7; P.A.K. by National Institutes of Health Grant GM29072; and U.C. by the Deutsche Forschungsgemeinschaft, Grant Ch 95/6-2.

  • Abbreviations used are::
    HMG-CoA
    3-hydroxy-3-methylglutaryl-coenzyme A
    AUC
    area under the curve
    CYP
    cytochrome P450
    HOMO
    highest occupied molecular orbital
    LC
    liquid chromatography
    MD
    molecular dynamics
    MM/PBSA
    molecular mechanics/Poisson-Boltzmann surface area
    MS
    mass spectrometry
    QM/MM
    quantum mechanics/molecular mechanics
    • Received April 10, 2000.
    • Accepted July 27, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 28 (11)
Drug Metabolism and Disposition
Vol. 28, Issue 11
1 Nov 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Lactonization Is the Critical First Step in the Disposition of the 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitor Atorvastatin
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Lactonization Is the Critical First Step in the Disposition of the 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitor Atorvastatin

Wolfgang Jacobsen, Bernd Kuhn, Andrea Soldner, Gabriele Kirchner, Karl-Fr. Sewing, Peter A. Kollman, Leslie Z. Benet and Uwe Christians
Drug Metabolism and Disposition November 1, 2000, 28 (11) 1369-1378;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Lactonization Is the Critical First Step in the Disposition of the 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitor Atorvastatin

Wolfgang Jacobsen, Bernd Kuhn, Andrea Soldner, Gabriele Kirchner, Karl-Fr. Sewing, Peter A. Kollman, Leslie Z. Benet and Uwe Christians
Drug Metabolism and Disposition November 1, 2000, 28 (11) 1369-1378;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • BSEP Function in Suspension Hepatocytes
  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics